Novel antidiabetic therapies in patients with peripheral artery disease: current perspective

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective

Saved in:

Bibliographic Details
Main Authors:	Miodrag Janić, Viviana Maggio, Andrej Janež, Manfredi Rizzo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Clinical Diabetes and Healthcare
Subjects:	peripheral artery disease type 2 diabetes mellitus SGLT-2 inhibitors GLP-1 receptor agonist GIP/GLP-1 receptor agonists
Online Access:	https://www.frontiersin.org/articles/10.3389/fcdhc.2024.1517265/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Incretin-Based Therapies and Cancer: What’s New?
by: Sanja Medenica, et al.
Published: (2025-04-01)

Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
by: Wenwen Zheng, et al.
Published: (2025-08-01)

Tirzepatide - role in obesity, health and physical wellness. Information overview
by: Anna Hanslik, et al.
Published: (2025-02-01)

Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan
by: Zong‐Yu Shen, et al.
Published: (2025-08-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Cardiodiabetology: Evolution or Revolution?
by: I. Z. Bondarenko, et al.
Published: (2025-02-01)

Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
by: Mohsina Patwekar, et al.
Published: (2025-01-01)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization
by: Deng G, et al.
Published: (2025-04-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
by: Ping-Tao Tseng, et al.
Published: (2025-04-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors
by: Jiann-Jy Chen, et al.
Published: (2025-05-01)

Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes
by: Karolina Mędrysa, et al.
Published: (2025-06-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
by: Jingyi Guo, et al.
Published: (2025-03-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-11-01)

Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses
by: Hsuan-Wen Lai, et al.
Published: (2025-03-01)

Innovations in Pharmacotherapy of Diabetes: A Review of Latest Reports
by: Katarzyna Czechowska, et al.
Published: (2025-07-01)

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
by: Mohammed Ali Gameil, et al.
Published: (2024-12-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01)

Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs
by: Huize Gao, et al.
Published: (2025-06-01)

Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease
by: Elias John Elenjickal, et al.
Published: (2024-12-01)

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists
by: Haoran Jiang, et al.
Published: (2025-08-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
by: Zhiyuan Cheng, et al.
Published: (2024-10-01)

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
by: Maria S Varughese, et al.
Published: (2025-03-01)

Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
by: Sohail Bade, et al.
Published: (2024-09-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials
by: Hazem Ayesh, et al.
Published: (2024-08-01)